Introduction {#s0005}
============

Image guided radiation therapy (IGRT) refers to the application of imaging during the entire radiation therapy (RT) process. This includes diagnosis, visualisation and delineation of the target volume (TV) during RT planning and geometric verification prior to, and in some cases, during treatment delivery. The focus of this paper is the application of IGRT in TV localisation and delineation.

The goal of all RT treatment is to deliver a precise radiation dose to a delineated TV while minimising dose to surrounding Organ at Risk (OAR) structures. TV and OAR delineation is completed on CT planning scans. CT imaging remains the gold standard imaging modality for RT treatment planning (RTP) due to its ability to convert Hounsfield units into electron densities that produce dose calculations in treatment planning systems [@b0005], [@b0010], [@b0015]. However one limitation of CT imaging is the soft tissue contrast achieved when compared to other imaging modalities such as Magnetic Resonance Imaging (MRI) [@b0020], [@b0025], [@b0030]. Suboptimal images may lead to uncertainties and inconsistencies in TV and OAR delineation.

The administration of Intravenous Contrast (IVC) enhances CT scans by differentiating vascular and non-vascular tissues, facilitating accurate TV and OAR delineation [@b0035], [@b0040], [@b0045], [@b0050], [@b0055], [@b0060]. In 2004, the UK Royal College of Radiologists (RCR) published a report 'Imaging for Oncology', recommending IVC for nine specific tumour sites in RT, they also suggested that it may be used for an additional eleven sites [@b0065] ([Table 1](#t0005){ref-type="table"}). Despite these published recommendations, there are variations in the routine application of IVC in clinical practice in RT. Clinical experience and expertise, clinical trial protocols and/or consensus contouring atlases are factors attributed to these variations [@b0055], [@b0070], [@b0075]. In 2008, Kim *et al*. found that 76% of the responding centres in a UK wide study used IVC for at least one of the nine recommended cancer sites, no department administered IVC for all nine of the recommended sites and 54% wished to administer it to additional tumour sites [@b0075]. In 2016, Williams *et al.* published a follow-up study and found that 98% of these centres deliver IVC to all nine recommended tumour sites [@b0070], but no department administered contrast to all of the RCR suggested sites Some recommendations from the study stated concerns for patient safety during IVC procedure and the need for definitive regulations and guidelines to ensure patient safety [@b0070].Table 1The UK Royal College of Radiologists guidelines for intravenous contrast use during the radiation therapy planning scan [@b0065].UK Royal College of Radiologists tumour sites IVC guidelinesRecommended Tumour SitesSuggested Tumour Sites1.Pharynx (including nasopharynx; oropharynx and hypopharynx)2.Nodal disease in the neck from head and neck cancer or other sites3.Lung4.Liver5.Pancreas6.Stomach7.Cholangiocarcinoma8.Oesophagus9.Kidney1.Hodgkin\'s Disease2.Non-Hodgkin\'s Disease3.Salivary glands4.Cervix5.Endometrium/ovary6.Rectum7.Larynx8.Colon9.Vulva10.Bladder11.Adrenal glands

While IVC agents today are 5--10 times safer than ionic agents used in the past, there are still associated risks with its use [@b0080]. Adverse effects from IV iodine-based contrast media can be categorised into non-renal adverse reactions (e.g. itching, bronchospasm, convulsions) or renal adverse reactions (i.e. Post-Contrast Acute Kidney Injury (PC-AKI)) [@b0085]. Hunt et al. investigated the characteristics of adverse effects from a cohort of 450,000 doses and reported hives and nausea as the most common adverse side effects and also, some rare fatalities [@b0090]. Irish Radiation Oncologists are affiliated with the Faculty of Radiologists at the Royal College of Surgeons in Ireland. The Irish Faculty of Radiologists have no policy on IVC use or administration, for this reason international guidelines are consulted. Guidelines on the administration of contrast and the management of adverse reactions are available from the European Society of Urogenital Radiology (RSUR) [@b0085], [@b0095], [@b0100] and the Royal Australian and New Zealand College of Radiologists (RANZCR) (The RANZCR guidelines are endorsed by the UK RCR) [@b0105]. Despite clear guidance, compliance with these guidelines within radiology departments' is often poor [@b0110].

The primary aim of the study is to examine the patterns of practice in relation to use of IVC in RTP in Ireland and to determine the level of compliance and consistency in use for the disease sites and specific patient safety issues. RTT IVC training will also be investigated.

Materials and methods {#s0010}
=====================

Ethical approval to complete this study was obtained from the School of Medicine Research Ethics Committee in Trinity College Dublin and the St Luke's Radiation Oncology Network Research Management Committee, Dublin and all data collection was in accordance with General Data Protection Regulation.

IVC guidelines {#s0015}
--------------

For the purpose of this study, the UK RCR 'Imaging for Oncology' (2004) guidelines were used as the standard to determine the tumour sites where IVC should and could be used [@b0065] ([Table 1](#t0005){ref-type="table"}). It could be argued that these guidelines are outdated with the advances in RT imaging and treatment, however there is an absence of alternative comprehensive recommendations and these guidelines were used previously for similar RT studies, making comparisons more meaningful with international practice. The UK RCR also publish guidelines on the administration of IVC, however they have recently endorsed the RANZCR Iodinated Contrast Guidelines (2016). Consequently the RANZCR so these guidelines were used for patient safety comparisons in the survey. National IVC guidelines from the Irish Institute of Radiography and Radiation Therapy (IIRRT - the professional body representing RTTs in Ireland) [@b0115] were also reviewed. These guidelines did not inform the survey development because they did not provide specific recommendations for renal testing but rather referred to the ESUR and the UK RCR (who now endorse the RANZCR) guidelines [@b0100], [@b0105]. Hence, the ESUR and RANZCR recommendations were used for practice comparisons in patient safety and PC-AKI assessment ([Table 2](#t0010){ref-type="table"}).Table 2Recommendations from The Royal Australian and New Zealand College of Radiologists (RANZCR) and The European Society of Urogenital Radiology (ESUR) guidelines on the administration of iodinated contrast.RANZCR GuidelinesESUR Guidelines1.Renal function testing: who and how?Renal function testing should be assessed if the patient(a)has known kidney disease or(b)presence of diabetes or(c)taking a drug containing metforminRenal function testing should be assessed if the patienta.has a known eGFR less than 60 ml/min/1.73 m^2^ orb.will receive intra- arterial contrast medium orc.aged over 70 ord.at risk of reactionEstimated Glomerular Filtration Rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration proposed equation (CKD-EPI) should be used to assess renal function2.Risk groups intravenous contrast media related post-contrast acute kidney injury (PC-AKI)eGFR of less than 45 ml/min/1.73 m^2^ is a risk factor for PC-AKIThe risk of PC-AKI is likely to be non-existent for patients with eGFR greater than 45 mL/min/1.73 m^2^The risk of PC-AKI with eGFR ≥ 30 ml/min/1.73 m^2^ is very lowLow or non-existent risk for patients with eGFR 30--45 mL/min/1.73 m^2^Preventive measures are recommended for patients with eGFR \< 45 ml/min/1.73 m^2^ if they are in ICUeGFR less than 30 ml/min/1.73 m^2^ or actively deteriorating renal function the risk versus the benefit should be carefully consideredPreventive measures are recommended for patients with eGFR \< 30 ml/min/1.73 m^2^ before intravenous

A comprehensive anonymised online survey was designed using SurveyMonkey Inc. to describe current IVC practice in Irish departments ([Appendix A](#s0060){ref-type="sec"}). The IVC questions in the survey were taken or adapted from similar research published in this area [@b0070], [@b0075], [@b0120] and based on the UK RCR 'Imaging for Oncology' publication [@b0065]. The questions relating to patient safety and PC-AKI were informed by the ESUR and RANZCR guidelines [@b0100], [@b0105]. Additional questions were added to investigate the participants' perception of guidelines.

To promote objectivity and minimise researcher bias, the survey included both qualitative and quantitative questions [@b0125] with open and closed and Likert Scale questions. The survey was piloted on a small number of radiation therapists (RTTs) to ensure the questions, participant information leaflets and consent forms were comprehensible and appropriately addressed the research question. All data collected was anonymous and non-identifiable.

An Executive Officer unrelated to the research team acted as the gatekeeper. Each of the twelve RT departments in the Republic of Ireland were invited to participate in the survey by the gatekeeper via email containing a link to the online survey. Radiation Therapy Service Managers were asked to designate a suitably qualified RTT in their respective departments to complete the survey. The survey was open for a four-week period in September- October 2018, with a reminder email sent by the gatekeeper one week before the closing date.

Completed surveys were exported to Microsoft Office 365 Excel for analysis using descriptive statistics (percentages, mode and mean). Departments were labelled from 'A' to 'I' to illustrate results.

Results {#s0020}
=======

75% of RT departments responded to the survey (*n* = 9/12) and all nine departments fully completed the survey.

RTTs cannulated patients in 67% (*n* = 6) of departments that responded. Nurses and junior doctors were responsible for cannulation in the remaining 33.3% (*n* = 3) departments. IVC administration was completed by RTTs in all departments. IVC protocols were based on diagnostic imaging protocols in eight out of nine responding departments, with the final department adapting diagnostic imaging protocols to achieve 'improved results' When asked if their department's current protocol was adequate, all respondents 'agreed' (*n* = 7) or 'strongly agreed' (*n* = 2). When asked if enhancement achieved from current IVC protocols was sufficient, 22% responded it was 'always' sufficient, while the remainder stated that it was in 'most cases'. The consistent scan enhancement reported was by the two departments where additional administrative techniques were used (saline chaser (*n* = 2) and bolus tracking (*n* = 1)). No other departments used additional enhancement techniques. Where IVC use was contraindicated 33% of departments fused the planning scan with a diagnostic scan for delineation purposes while the remainder took no further action.

IVC use {#s0025}
-------

All responding departments used IVC in clinical practice to varying degrees. IVC enhanced CT scans made up 10%-60% (Mean 35%, Median 30%) of the total monthly CT output in responding departments ([Fig. 1](#f0005){ref-type="fig"}). Three departments stated that ≥50% of patients per month required contrast, while six departments used contrast for \<50% of patients scanned. One department stated that IVC was administered for approximately 10% of their patients.Fig. 1The frequency of intravenous contrast (IVC) usage per department per month.

Four departments used IVC for ≥16 sites, eight departments used IVC for ≥10 different tumour sites, while one department used IVC for four tumour sites. [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"} illustrate the range of sites where IVC is administered. 33% (*n* = 3) departments stated that they had plans for improving/extending their use of IVC while 66% (*n* = 6) of respondents had no future plans to do so. Two departments responded when asked the reason why IVC was not routinely used in their departments, they identified staff training (*n* = 1) and the lack of hospital policy surrounding IVC use (*n* = 1) as reasons.Fig. 2Usage of intravenous contrast (IVC) for radiation therapy planning scans based on the Royal College Radiologists (RCR) guidelines.Fig. 3The range of tumour sites (excluding the RCR sites) where intravenous contrast (IVC) is administered during radiation therapy planning scans.

RCR tumour sites {#s0030}
----------------

The RCR recommends [@b0065] using IVC routinely for 9 sites ([Table 1](#t0005){ref-type="table"}). No department administered IVC to all nine recommended sites ([Fig. 2](#f0010){ref-type="fig"}). Three departments administered contrast to six of the nine recommended sites. The nine responding departments reported routine use of IVC for head and neck patients (*n* = 9), followed by lung (*n* = 8), pancreas (*n* = 7) and pharynx/oesophagus patients (both *n* = 5). IVC use was less common in the other RCR recommended tumours; with one department routinely administered IVC for cholangiocarcinoma (*n* = 1) while two departments routinely administered IVC for liver patients (*n* = 2).

The RCR guidelines suggest the IVC can be used in an additional 11 sites ([Fig. 3](#f0015){ref-type="fig"}). No department administered IVC to all these suggested sites. Hodgkin's Lymphoma was the most common site where contrast was given (87%, *n* = 8); followed by endometrium; cervix; parotid and Non Hodgkin's Lymphoma, with 7 departments (78%) administer IVC to these sites. Several sites were identified to which centres gave IVC which are not supported by the RCR ([Fig. 3](#f0015){ref-type="fig"}) including: prostate (*n* = 6); brain and paranasal sinus (*n* = 5) and thyroid (*n* = 4).

Patient safety {#s0035}
--------------

Prior to IVC administration, the vast majority of departments (*n* = 8/9) routinely checked the kidney function for every patient. One department routinely checking kidney function for high-risk patients only. RTTs were responsible for checking kidney function in 78% of departments (*n* = 7), while a diagnostic radiographer (*n* = 1) and nursing staff (*n* = 1) were responsible in the other departments.

Five departments used estimated Glomerular Filtration Rate (eGFR) to assess kidney function, using a variety of different calculations to assess this: the Cockcroft Gault formula (*n* = 2); the Modification of Diet in Renal Disease (MDRD) formula (*n* = 2) and one department did not know the formula used to calculate eGFR. Four other departments assessed kidney function by measuring creatinine levels. Where departments used eGFR to assess kidney function, the most common eGFR threshold where IVC can be administered without intervention was \>60 mL/min/1.73 m^2^ (75% *n* = 3) and a lower limit of \<30 mL/min/1.73 m^2^ (50% *n* = 2), where no contrast is administered. The intervention ranges were as follows: eGFR 45--59 mL/min/1.73 m^2^ 1 l oral hydration over 2 h (*n* = 2) and eGFR30-44 mL/min/1.73 m^2^, 1 l IV hydration over 2 h (*n* = 2) or \>45 mL/min/1.73 m^2^ a doctor was required to make the decision (*n* = 1) One department did not provide the eGFR bands.

Eight departments (89%) offered post contrast advice to patients, the advice focusing on remaining vigilant for signs and symptoms of a delayed reaction and the importance of increasing oral hydration to aid IVC excretion. One department reported that no advice was given post procedure. Information regarding extravasation was provided to patients in most of the departments (89%, *n* = 8), in one department the advice given was unknown.

Training {#s0040}
--------

All training received covered cannulation and IVC administration procedures. The training was largely university based in 78% (*n* = 7) of the responding departments, with the remaining two departments using an IIRRT accredited hospital based training programme. The duration of training varied, ranging from two days to two months with the training structure composed of a taught theory component followed by a period of supervised cannulations and administrations. The supervised cannulations ranged from 20 to 40 patients and the supervised administration ranged from 3 to 20 patients. When asked if the training they received was sufficient, 78% (*n* = 7) of departments agreed. 78% of departments also agreed (strongly agreed = 5; agreed = 2) that they were confident in delivering IVC post the completion of training. When asked if guidelines are required for standardising IVC training five departments agreed and three departments strongly agreed ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4Participants' response to guideline related questions.

Guideline need {#s0045}
--------------

The response to questions relating to guidelines is shown in [Fig. 4](#f0020){ref-type="fig"}. All departments agreed (*n* = 3) or strongly agreed (*n* = 6) that guidelines are needed to standardise patient safety when administering IVC. Two-thirds for departments agreed that guidelines are needed to identify site where IVC should be used.

Discussion {#s0050}
==========

IVC can enhance the IGRT capability of RTP CT imaging. Accurate TV and OAR delineation requires high quality imaging scans and many studies endorse the use of IVC in RTP scans reporting consistent and accurate structure delineation in a range of sites [@b0035], [@b0040], [@b0130], [@b0135], [@b0140]. This study presents the current pattern of IVC practice in RTP scans in Ireland and identifies compliances and discrepancies with international recommended guidelines. This study can provide a practice comparison and learning for departments beyond Ireland.

The survey response rate (75%, *n* = 9/12) is an adequate representation of current IVC practices in Ireland. Although each of the responding departments stated that they used IVC, there were inconsistencies in practice ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). All of the Irish departments surveyed used IVC in clinical practice, which is similar to the UK use (98%) reported in 2014 [@b0070].

No Irish department administered IVC to all nine of the RCR recommended tumour sites, while 6% of UK departments are fully compliant with these recommendations [@b0070]. However, these results may not reflect poor compliance within Irish departments as small departments may refer less common disease sites (e.g. cholangiocarcinoma) to larger referral centres, thus not routinely imaging the range of RCR recommended sites. A third of Irish departments administered contrast to six of the nine recommended sites, with all departments using IVC for head and neck nodes, which is also in line with current evidence based contouring recommendations [@b0145]. Despite the RCR recommendations and evidence to suggest the benefit of IVC in TV and OAR delineation [@b0065], [@b0145], [@b0150], [@b0155], IVC use was less routine in the stomach (*n* = 3/9); pharynx (*n* = 5/9) and oesophagus (*n* = 5/9).

The use of IVC has increased over the last decade based largely on consensus delineation guidelines and clinical trial protocols [@b0070]. This is reflected in the usage reported in this study in the suggested RCR sites such as Non/Hodgkin's lymphoma; gynaecological disease sites; prostate; parotid and rectum, proposing that these sites should now have a definitive recommendation for IVC. There was a similar compliance in department IVC practice between the recommended and suggested RCR sites, this is also in line with the UK findings [@b0160]. Sites where IVC was commonly given but not recommended or suggested in the RCR guidelines include prostate, brain and paranasal sinuses. The use of IVC at these sites reflects new evidence for its benefit in CT imaging [@b0055], [@b0145] since the establishment of the RCR guidelines and is similar to the UK results [@b0070]. These results may suggest a need to review and update the RCR recommended sites in view of evidenced based practice.

Two thirds of departments were in favour of the introduction of guidelines specifying the tumour sites where IVC is beneficial for TV and OAR delineation. UK RTTs also support this motion [@b0070]. Such guidelines could facilitate the standardisation of IVC use in RTP scans. A more definitive list of sites where IVC use is warranted may support the increased use of contrast, for example by including the 11 suggested sites to the recommended list in the RCR guidelines. It can be argued that guidelines may not directly translate into a change in practice. However, there is evidence in the case of prostate, where consensus delineation guidelines for pelvic nodal volumes have recommended the use of IVC [@b0055] and 67% (*n* = 6/9) departments use contrast in this patient group. Collaboration at a multidisciplinary level may be key to developing consistent practice guidelines. The knowledge and experience of diagnostic radiographers; radiation oncologists and radiologists should be harnessed to create and optimise IVC protocols for RT planning scans.

RANZCR and ESUR guidelines recommend assessing renal function in patients at risk of PC-AKI only ([Table 2](#t0010){ref-type="table"}). One department adhered to these recommendations while the remainder assessed renal functions in all patients. These inconsistencies may be due to following older RCR guidelines which recommended assessing renal function for all non-emergency patients [@b0165] and departments maintaining a cautious approach to patient safety. Assessing only high risk patients would streamline the pre-CT process by reducing the number of patients requiring biochemistry tests before IVC which requires a waiting period between taking blood and receiving results.

Inconsistencies were observed in the methods of assessing renal function across the different departments. Total glomerular filtration rate (GFR) is considered the best measure of kidney function, but it cannot be easily assessed in clinical practice, for that reason eGFR using serum creatinine levels is routinely used [@b0085]. There are several different equations proposed to calculate eGFRs [@b0085]. RANZCR and ESUR guidelines recommend measuring the eGFR using the Chronic Kidney Disease Epidemiology (CKD-EPI) proposed equation due to its accuracy across a wide variety of populations and clinical conditions when compared with other formulae issues [@b0170], [@b0175], [@b0180]. Although 44% of departments used eGFR, different formulas were used to calculate this reading, with no department using the CKD-EPI equation. Four of the nine (44%) Irish department and 27% of UK departments [@b0070] tested renal function using serum creatinine levels alone. Serum creatinine can fail to recognise patients with impaired kidney function in up to 92% of patient \>70 years of age [@b0180]. Indications for serum creatinine substitutes and formula specific eGFR measures can present as conflicting and possibly confusing. Highlighting these inconsistencies in renal function testing may help inform future policies and practice for departments.

The RANZCR and ESUR guidelines state that eGFR of less than 45 ml/min/1.73 m^2^ is a risk factor for PC-AKI but above this level, the risk is likely to be non-existent and no intervention is required ([Table 2](#t0010){ref-type="table"}). In addition, they state that IVC can still be considered at \<30 ml/min/1.73 m^2^ if the benefit outweighs the risk of PC-AKI on the patient [@b0105] and preventive measures such as intensive hydration protocols prior to administration are followed [@b0085], [@b0095] ([Table 2](#t0010){ref-type="table"}). The reported results were inconsistent between departments and are more conservative than the recommendations; with a threshold of hydration intervention from 45 to 59 mL/min/1.73 m^2^. All departments that assess eGFR had a lower cut off for IVC use of 30--45 mL/min/1.73 m^2^. This conservative approach by departments is reasonable and may reflect clinical experiences and the balance of risk coming down on the side of preventing PC-AKI versus the benefit of image enhancement. The guidelines propose that if the benefits exceed the risk then IVC can be considered even at levels below 30 mL/min/1.73 m^2^, this approach may allow an increased number of patients benefit from contrast enhancement, especially in the context where 67% of departments did not use additional imaging methods to aid delineation when contrast was not used.

Risks of adverse reactions associated with IVC are well reported [@b0090] and both the RANZCR and ESUR have an established escalation procedure in the event of adverse reactions [@b0085], [@b0095], [@b0105]. The majority of departments (87%) provided patients with advice regarding delayed reactions and hydration post the IVC procedure. The safety of the patient is fundamental in any RT procedure including IVC use. In line with RANZCR recommendations, all RTTs should be trained in the signs and symptoms of early and late adverse reactions and the escalation procedures to address such reactions. This will ensure RTTs are competent in identifying and dealing with any safety issues that may arise during IVC process.

Cannulation and IVC administration is largely RTT led, with RTTs cannulating patients in 67% of departments and administering IVC in all departments. Inconsistencies were reported in many aspects of IVC training (duration, number of supervised cannulations and administrations), similar to findings from other countries [@b0070]. The majority of participants felt the training was sufficient and were confident in administering IVC post training. One department reported the theoretical component of the training was inadequate and one department referred to staff training as a barrier to the expansion of IVC use. Training programmes in Ireland are delivered by and for diagnostic radiographers. The programmes have a strong focus on the practical aspects of cannulation as it is assumed that participants have prior knowledge of the theoretical aspects of IVC, as a result, they may not meet the educational needs of RTTs.

Advanced techniques such as saline chaser and bolus tracking were used routinely in a third of departments. The two departments who reported achieving consistent image enhancement with IVC routinely use bolus tracking and saline chaser. Both techniques are cost effective, reduce risk of CI nephropathy and are beneficial in CT enhancement when used correctly [@b0185], [@b0190], [@b0195]. While it is positive that cannulation and IVC administration is largely RTT led, inconsistencies exist in training received in optimisation techniques in IVC administration. Throughout their careers, RTs may work in several departments bringing with them their own cannulation and IVC practices. This could lead to a department where practices may be dependent on the RTT completing the cannulation and IVC administration. Eight of the nine departments were in favour of guidelines to standardise IVC training programmes, which is to be expected based on the variations reported. Lack of standardisation and inconsistencies in practice may prove difficult for new staff training and building competencies in this area potentially jeopardising the effectiveness and safety of this procedure. A standardised training programme focused on RT practice may provide the basis for much needed consistency in cannulation practices and guidelines for maximising IVC function and capabilities thus optimising image quality.

Limitations

A limitation of this study was the lack of full participation of all departments (*n* = 9/12). Departments without IVC facilities may have assumed the survey was not applicable to them. Full participation in the study would provide a fully comprehensive picture of IVC use throughout Ireland Departments were not asked to provide their clinical IVC protocol. It is also possible respondents may not have clearly understood or have been biased by the wording in this survey. Given the small sample of centres (*n* = 12) it was not practical to pilot the questions on RTTs from other centres. There may be discrepancies between what was captured in the survey and the implemented clinical protocol. The use of IVC may be physician dependent, rather than site/protocol dependent, this point was not captured in the survey.

Conclusion {#s0055}
==========

IVC is used routinely in clinical practice in Ireland but there are inconsistencies in its application. There is heterogeneity in terms of: the disease sites where IVC is warranted; the assessment of patients' renal function prior to contrast administration and the RTT IVC training. A lack of definitive guidelines may mean the proven benefits of IVC in facilitating TV and OAR delineation is not being fully maximised. The findings of this study are based on the Irish context, however the insights offered into IVC practice can provide learning for departments in other countries.

Recommendations to departments using IVC include:•IVC should be implemented into routine clinical practice for all sites where its use has shown superior image interpretation thus facilitating accurate TV and OAR delineation. In the absence of other evidence, the 20 sites identified by the UK RCR 'imaging for Oncology' publication provides guidance on appropriate IVC use [@b0065].•eGFR levels can be checked for patients 'at risk' of PC-AKI only. This 'at risk' group can be identified by reference to the EURS guidelines [@b0100].•Standardised RTT training for IVC cannulation and administration should provide RTTs with the skills to implement image enhancement techniques and maximise benefits of IVC where required.
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